Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
Bile duct cancer is rare as cancers go with about 8000 diagnoses in the United States annually. Like many rare cancers, conventional oncology offers few if any effective therapies.
It is for this reason that those diagnosed with bile duct cancer may want to step outside of the limitations of conventional oncology and consider evidence-based integrative therapies. According to the research linked below, curcumin enhances the efficacy of gemcitabine against gemcitabine-resistant bile duct cancer.
I am a long-term cancer cancer survivor and cancer coach. When I reached end-stage myeloma (my type of blood cancer), I researched therapies that were outside the realm of FDA approved, standard-of-care therapies.
There are pros and cons with both conventional and non-conventional therapies. I am simply saying that if a cancer patient is faced with limited therapies, he/she may want to look beyond the world of conventional oncology.
If you would like to learn more about both conventional and non-conventional cancer therapies, email me at David.PeopleBeatingCancer@gmail.com
Thank you,
“Cholangiocarcinoma (CCA) is often diagnosed late, leading to incomplete tumor removal, drug resistance and reduced chemotherapy efficacy. Curcumin has the potential for anti-cancer activity through various therapeutic properties and can improve the efficacy of chemotherapy.
We aimed to investigate the synergistic effect of a combination of curcumin and gemcitabine against CCA, targeting the LAT2/glutamine pathway. This combination synergistically suppressed proliferation in gemcitabine-resistant CCA cells (KKU-213BGemR).
It also resulted in a remarkable degree of CCA cell apoptosis and cell cycle arrest, characterized by a high proportion of cells in the S and G2/M phases. Knockdown of SLC7A8 decreased the expressions of glutaminase and glutamine synthetase, resulting in inhibited cell proliferation and sensitized CCA cells to gemcitabine treatment.
Moreover, in vivo experiments showed that a combination curcumin and gemcitabine significantly reduced
Suppression of tumor progression in an orthotopic CCA hamster model provided strong support for clinical application. In conclusion, curcumin synergistically enhances gemcitabine efficacy against gemcitabine-resistant CCA by induction of apoptosis, partly via inhibiting LAT2/glutamine pathway. This approach may be an alternative strategy for the treatment of gemcitabine-resistant in CCA patients…
Cholangiocarcinoma is a cancer with poor prognosis. Patients usually present at a late stage, leading to high morbidity and mortality, and poor response to drug treatment.
Here, we established a drug-resistant CCA cell line (KKU-213BGemR) to test the therapeutic effect of a combination of curcumin and gemcitabine in CCA both in vivo and in vitro, especially in resistant CCA cell lines.
The results showed that the combination of curcumin and gemcitabine was effective in treating resistant CCA cells, in part reducing expression of the LAT2/glutamine pathway, as summarized in Fig. 8…
“Bile duct cancer is a rare disease in which malignant (cancer) cells form in the bile ducts. Bile duct cancer is also called cholangiocarcinoma.
A network of tubes, called ducts, connects the liver, gallbladder, and small intestine. This network begins in the liver where many small ducts collect bile (a fluid made by the liver to break down fats during digestion). The small ducts come together to form the right and left hepatic ducts, which lead out of the liver. The two ducts join outside the liver and form the common hepatic duct. The cystic duct connects the gallbladder to the common hepatic duct. Bile from the liver passes through the hepatic ducts, common hepatic duct, and cystic duct and is stored in the gallbladder.
When food is being digested, bile stored in the gallbladder is released and passes through the cystic duct to the common bile duct and into the small intestine..”